Literature DB >> 1594239

Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.

G Chenevix-Trench1, J Leary, J Kerr, J Michel, R Kefford, T Hurst, P G Parsons, M Friedlander, S K Khoo.   

Abstract

Inactivation of the DCC gene on chromosome 18 owing to loss of heterozygosity is a common finding in colorectal cancer. Because both ovarian and colon cancer are features of Lynch syndrome II, which has been provisionally mapped to chromosome 18, we hypothesized that loss of heterozygosity at the DCC locus may also occur in ovarian neoplasia. Fifty-two sporadic ovarian adenocarcinoma tumours were analysed by Southern blotting for loss of heterozygosity (LOH) at six chromosome 18 loci. Overall, tumours from 31 patients (60%) showed allelic loss at one or more of these loci. A similarly high level of LOH, 66%, was found at D17S5 (17p13.3). In contrast, moderate levels of LOH, of 31%, 39% and 33%, were found at MYCL1 (1p32), D1S57 (1p) and D14S20 (14q32.33) respectively. However, analysis of partial chromosome deletions in 11 patients indicates that the smallest region of overlap appears to exclude the DCC gene but to be between the D18S5 and D18S11 loci. This suggests that another locus, as well as or apart from DCC, may be involved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594239

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

Authors:  H Lassus; R Salovaara; L A Aaltonen; R Butzow
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident.

Authors:  C Wicking; S Shanley; I Smyth; S Gillies; K Negus; S Graham; G Suthers; N Haites; M Edwards; B Wainwright; G Chenevix-Trench
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

3.  The significance of the expression of tumor suppressor gene DCC in human gliomas.

Authors:  K Nakatani; N Yoshimi; H Mori; H Sakai; J Shinoda; T Andoh; N Sakai
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

4.  Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.

Authors:  Liu Meimei; Li Peiling; Li Baoxin; Li Changmin; Zhuang Rujin; Hu Chunjie
Journal:  Med Oncol       Date:  2010-01-07       Impact factor: 3.064

5.  Lower frequency of allele loss on chromosome 18q in human breast cancer than in colorectal tumors.

Authors:  M Schenk; C Leib-Mösch; I U Schenck; M Jaenicke; S Indraccolo; H D Saeger; G Dallenbach-Hellweg; R Hehlmann
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

6.  Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.

Authors:  G Chenevix-Trench; J Kerr; M Friedlander; T Hurst; B Sanderson; M Coglan; B Ward; J Leary; S K Khoo
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

7.  GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model.

Authors:  Deepak Kamnasaran; Baoping Qian; Cynthia Hawkins; William L Stanford; Abhijit Guha
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

8.  DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis.

Authors:  K Inokuchi; K Miyake; H Takahashi; K Dan; T Nomura
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

9.  Frequent loss of heterozygosity at the deleted in colorectal carcinoma gene locus and its association with histologic phenotypes in breast carcinoma.

Authors:  M Kashiwaba; G Tamura; M Ishida
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas.

Authors:  A Viel; L Dall'Agnese; F Simone; V Canzonieri; E Capozzi; M C Visentin; R Valle; M Boiocchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.